Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.

Sohei Satoi,Tsutomu Fujii,Hiroaki Yanagimoto,Fuyuhiko Motoi,Masanao Kurata,Naminatsu Takahara,Suguru Yamada,Tomohisa Yamamoto,Masamichi Mizuma,Goro Honda,Hiroyuki Isayama,Michiaki Unno,Yasuhiro Kodera,Hironori Ishigami,Masanori Kon

Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.

2017

Sohei Satoi
Tsutomu Fujii
Hiroaki Yanagimoto
Fuyuhiko Motoi
Masanao Kurata
Naminatsu Takahara
Suguru Yamada
Tomohisa Yamamoto
Masamichi Mizuma
Goro Honda
Hiroyuki Isayama
Michiaki Unno
Yasuhiro Kodera
Hironori Ishigami
Masanori Kon

Objective:To evaluate the clinical efficacy and tolerability of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel combined with S-1, “an oral fluoropyrimidine derivative containing tegafur, gimestat, and otastat potassium” in chemotherapy-naive pancreatic ductal adenocarcinoma (PDAC) patients

Keywords:

Tegafur
Surgery
Paclitaxel
Phases of clinical research
Metastasis
Medicine
Adenocarcinoma
Tolerability
pancreatic ductal adenocarcinoma
Peritoneal Neoplasm
Carcinoma
peritoneal metastasis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations